Page 292 - Binder2
P. 292
In a world confronting climate pressure, water scarcity, and
supply chain disruption, this isn’t a niche benefit—it’s a
strategic edge.
Cost Reductions Across the Board
When you remove bioreactors, cleanrooms, and cold-chain
infrastructure, you’re not just innovating—you’re
unlocking massive cost savings.
• Capex savings: No need for $500M GMP facilities
• OpEx savings: No bioreactor runs, sterile filtration,
or cold-chain monitoring
• Labor savings: Less technical labor, fewer
specialized roles
• Distribution savings: Shelf-stable product =
simplified global reach
• Administration savings: No nurse, no clinic, no
pre-authorization for infusion
The cumulative effect? Biologic therapy at a fraction of the
cost—with potential for higher margins, broader access,
and faster global scale.
A Paradigm Shift, Not Just a Price Drop
It’s tempting to see edible biologics as a cost-reduction
strategy. But that undersells the disruption. This isn’t a
cheaper way to do the same thing. It’s a fundamentally
different model of what a drug can be.
Edible biologics don’t just eliminate infrastructure—they
reimagine where, how, and by whom biologics are made
290
